Literature DB >> 21338871

The doctor's dilemma: opiate analgesics and chronic pain.

Howard L Fields1.   

Abstract

Opiates are utilized routinely and effectively as a short-term analgesic treatment for a variety of acute pain conditions such as occur following trauma, and for patients with painful terminal diseases such as cancer. Because opiate analgesics are highly addictive substances, their use in the treatment of chronic nonmalignant pain remains controversial.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21338871      PMCID: PMC3073133          DOI: 10.1016/j.neuron.2011.02.001

Source DB:  PubMed          Journal:  Neuron        ISSN: 0896-6273            Impact factor:   17.173


  14 in total

Review 1.  Regulation of opioid receptors by endocytic membrane traffic: mechanisms and translational implications.

Authors:  Mark von Zastrow
Journal:  Drug Alcohol Depend       Date:  2010-03-24       Impact factor: 4.492

Review 2.  Opioid tolerance and hyperalgesia.

Authors:  Grace Chang; Lucy Chen; Jianren Mao
Journal:  Med Clin North Am       Date:  2007-03       Impact factor: 5.456

3.  Absence of conditioned place preference or reinstatement with bivalent ligands containing mu-opioid receptor agonist and delta-opioid receptor antagonist pharmacophores.

Authors:  Natalie R Lenard; David J Daniels; Philip S Portoghese; Sandra C Roerig
Journal:  Eur J Pharmacol       Date:  2007-03-03       Impact factor: 4.432

4.  Incidence and antecedents of nonmedical prescription opioid use in four US communities. The Coronary Artery Risk Development in Young Adults (CARDIA) prospective cohort study.

Authors:  Mark J Pletcher; Stefan G Kertesz; Stephen Sidney; Catarina I Kiefe; Stephen B Hulley
Journal:  Drug Alcohol Depend       Date:  2006-05-24       Impact factor: 4.492

5.  Opioid-induced tolerance and dependence in mice is modulated by the distance between pharmacophores in a bivalent ligand series.

Authors:  David J Daniels; Natalie R Lenard; Chris L Etienne; Ping-Yee Law; Sandra C Roerig; Philip S Portoghese
Journal:  Proc Natl Acad Sci U S A       Date:  2005-12-19       Impact factor: 11.205

6.  Opioid receptor-mediated hyperalgesia and antinociceptive tolerance induced by sustained opiate delivery.

Authors:  Luis R Gardell; Tamara King; Michael H Ossipov; Kenner C Rice; Josephine Lai; Todd W Vanderah; Frank Porreca
Journal:  Neurosci Lett       Date:  2005-12-15       Impact factor: 3.046

Review 7.  Underlying mechanisms of pronociceptive consequences of prolonged morphine exposure.

Authors:  Michael H Ossipov; Josephine Lai; Tamara King; Todd W Vanderah; Frank Porreca
Journal:  Biopolymers       Date:  2005       Impact factor: 2.505

Review 8.  Opioids in chronic non-cancer pain: systematic review of efficacy and safety.

Authors:  Eija Kalso; Jayne E Edwards; Andrew R Moore; Henry J McQuay
Journal:  Pain       Date:  2004-12       Impact factor: 6.961

9.  Morphine-induced receptor endocytosis in a novel knockin mouse reduces tolerance and dependence.

Authors:  Joseph A Kim; Selena Bartlett; Li He; Carsten K Nielsen; Amy M Chang; Viktor Kharazia; Maria Waldhoer; Chrissi J Ou; Stacy Taylor; Madeline Ferwerda; Dragana Cado; Jennifer L Whistler
Journal:  Curr Biol       Date:  2008-01-22       Impact factor: 10.834

Review 10.  Opioid dependence and addiction during opioid treatment of chronic pain.

Authors:  Jane C Ballantyne; Steven K LaForge
Journal:  Pain       Date:  2007-05-04       Impact factor: 6.961

View more
  53 in total

1.  Chronic CRF1 receptor blockade reduces heroin intake escalation and dependence-induced hyperalgesia.

Authors:  Paula E Park; Joel E Schlosburg; Leandro F Vendruscolo; Gery Schulteis; Scott Edwards; George F Koob
Journal:  Addict Biol       Date:  2013-12-13       Impact factor: 4.280

2.  The Effects of Morphine, Baclofen, and Buspirone Alone and in Combination on Schedule-Controlled Responding and Hot Plate Antinociception in Rats.

Authors:  Jenny L Wilkerson; Jasmine S Felix; Luis F Restrepo; Mohd Imran Ansari; Andrew Coop; Lance R McMahon
Journal:  J Pharmacol Exp Ther       Date:  2019-06-24       Impact factor: 4.030

3.  The affective dimension of pain as a risk factor for drug and alcohol addiction.

Authors:  Dana M LeBlanc; M Adrienne McGinn; Christy A Itoga; Scott Edwards
Journal:  Alcohol       Date:  2015-05-01       Impact factor: 2.405

4.  Impact of an Electronic Pain and Opioid Risk Assessment Program: Are There Improvements in Patient Encounters and Clinic Notes?

Authors:  Stephen F Butler; Kevin L Zacharoff; Sadaf Charity; Ryan A Black; Emma Chung; Antje Barreveld; Molly S Clark; Robert N Jamison
Journal:  Pain Med       Date:  2016-04-20       Impact factor: 3.750

Review 5.  Understanding opioid reward.

Authors:  Howard L Fields; Elyssa B Margolis
Journal:  Trends Neurosci       Date:  2015-01-29       Impact factor: 13.837

Review 6.  Opioid receptor trafficking and interaction in nociceptors.

Authors:  X Zhang; L Bao; S Li
Journal:  Br J Pharmacol       Date:  2014-07-01       Impact factor: 8.739

Review 7.  Obstacles to the Prescription and Use of Opioids.

Authors:  Rachel S Wallwork; Fallon E Chipidza; Theodore A Stern
Journal:  Prim Care Companion CNS Disord       Date:  2016-02-18

8.  Development of mechanical hypersensitivity in rats during heroin and ethanol dependence: alleviation by CRF₁ receptor antagonism.

Authors:  Scott Edwards; Leandro F Vendruscolo; Joel E Schlosburg; Kaushik K Misra; Sunmee Wee; Paula E Park; Gery Schulteis; George F Koob
Journal:  Neuropharmacology       Date:  2011-11-23       Impact factor: 5.250

9.  The Development of a Macromolecular Analgesic for Arthritic Pain.

Authors:  Laura Weber; Xiaobei Wang; Rongguo Ren; Xin Wei; Gang Zhao; Junxiao Yang; Hongjiang Yuan; Huiling Pang; Hanjun Wang; Dong Wang
Journal:  Mol Pharm       Date:  2019-02-14       Impact factor: 4.939

10.  Inflated reward value in early opiate withdrawal.

Authors:  Kate M Wassum; Venuz Y Greenfield; Kay E Linker; Nigel T Maidment; Sean B Ostlund
Journal:  Addict Biol       Date:  2014-07-31       Impact factor: 4.280

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.